Some researchers have attempted to interfere with STAT3 activation and associated signaling as a strategy to ameliorate PF, and they found that a cell-permeable peptide inhibitor of STAT3 phosphorylation or STAT3 associated signaling pathway inhibitors might be a feasible therapeutic option for PF [30, 31]. The gene discussed is STAT3; the disease is pemphigus foliaceus.